Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.00 (+0.00%)
As of: Aug 21, 2026 · 2:38 PM EDT

Drugs Made In America Acquisition (DMII) Liabilities and Shareholders Equity (2024 - 2025)

Drugs Made In America Acquisition (DMII) posted quarterly Liabilities and Shareholders Equity of $505.0 million for Q4 2025, up 365643.31% year-over-year from N/an in Q4 2024, and up 0.79% quarter-over-quarter from $501.0 million in Q3 2025.

Drugs Made In America Acquisition (DMII) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Liabilities and Shareholders Equity for 2 consecutive years, with $505.0 million the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - 261.48 Mn
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - 245.80 Mn
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - 514.10 Mn
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - 464.99 Mn
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - 98.35 Mn
6 Aldel Financial 397.49 Mn 397.49 Mn - 247.73 Mn
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - 314.37 Mn
8 Gores Holdings X 385.06 Mn 384.87 Mn - 374.60 Mn
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - 376.80 Mn
10 CSLM Digital Asset Acquisition Corp III 322.52 Mn 314.90 Mn - 240.01 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 504.96 Mn
Sep 30, 2025 501.01 Mn
Dec 31, 2024 138,064.00